Combining TRAIL with PI3 Kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling

Yazar: Saturno, Grazia, Valenti, Melanie, De Haven Brandon, Alexis, Thomas, George V., Eccles, Suzanne, Clarke, Paul A., Workman, Paul
Baskı/Yayın Bilgisi 2013

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

Yazar: Sriskandarajah, Priya, De Haven Brandon, Alexis, MacLeod, Kenneth, Carragher, Neil O., Kirkin, Vladimir, Kaiser, Martin, Whittaker, Steven R.
Yayımlandı BMC Cancer (2020)

Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice

Yazar: De Haven Brandon, Alexis, Box, Gary, Hallsworth, Albert, Court, William, Matthews, Nicoll, Herodek, Balint, Arteagabeitia, Aitor Bermejo, Valenti, Melanie, Kirkin, Vladimir
Yayımlandı Sci Rep (2020)

Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypo...

Yazar: Yang, Jun, Ahmed, Afshan, Poon, Evon, Perusinghe, Nina, de Haven Brandon, Alexis, Box, Gary, Valenti, Melanie, Eccles, Suzanne, Rouschop, Kasper, Wouters, Brad, Ashcroft, Margaret
Baskı/Yayın Bilgisi 2009

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

Yazar: Zhang, Chi, Stockwell, Simon R., Elbanna, May, Ketteler, Robin, Freeman, Jamie, Al-Lazikani, Bissan, Eccles, Suzanne, De Haven Brandon, Alexis, Raynaud, Florence, Hayes, Angela, Clarke, Paul A., Workman, Paul, Mittnacht, Sibylle
Yayımlandı Oncogene (2019)

Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

Yazar: Zhang, Chi, Stockwell, Simon R., Elbanna, May, Ketteler, Robin, Freeman, Jamie, Al-Lazikani, Bissan, Eccles, Suzanne, De Haven Brandon, Alexis, Raynaud, Florence, Hayes, Angela, Clarke, Paul A., Workman, Paul, Mittnacht, Sibylle
Yayımlandı Oncogene (2020)

Enhanced efficacy of IGF1R inhibition in paediatric glioblastoma by combinatorial targeting of PDGFRα/β

Yazar: Bielen, Aleksandra, Perryman, Lara, Box, Gary M., Valenti, Melanie, de Haven Brandon, Alexis, Martins, Vanessa, Jury, Alexa, Popov, Sergey, Gowan, Sharon, Jeay, Sebastien, Raynaud, Florence I., Hofmann, Francesco, Hargrave, Darren, Eccles, Suzanne A., Jones, Chris
Baskı/Yayın Bilgisi 2011

Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo

Yazar: Renshaw, Jane, Taylor, Kathryn R., Bishop, Ryan, Valenti, Melanie, De Haven Brandon, Alexis, Gowan, Sharon, Eccles, Suzanne A., Ruddle, Ruth R., Johnson, Louise D., Raynaud, Florence I., Selfe, Joanna L., Thway, Khin, Pietsch, Torsten, Pearson, Andrew D., Shipley, Janet
Baskı/Yayın Bilgisi 2013

Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

Yazar: Moore, Andrew S., Faisal, Amir, de Castro, David Gonzalez, Bavetsias, Vassilios, Sun, Chongbo, Atrash, Butrus, Valenti, Melanie, de Haven Brandon, Alexis, Avery, Sian, Mair, Debbie, Mirabella, Fabio, Swansbury, John, Pearson, Andrew D.J., Workman, Paul, Blagg, Julian, Raynaud, Florence I., Eccles, Suzanne A., Linardopoulos, Spiros
Baskı/Yayın Bilgisi 2012

Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation

Yazar: Ang, Joo Ern, Pandher, Rupinder, Ang, Joo Chew, Asad, Yasmin J, Henley, Alan, Valenti, Melanie, Box, Gary, de haven Brandon, Alexis, Baird, Richard R., Friedman, Lori, Derynck, Mika, Vanhaesebroeck, Bart, Eccles, Suzanne A, Kaye, Stan B, Workman, Paul, de Bono, Johann S, Raynaud, Florence I
Yayımlandı Mol Cancer Ther (2016)

Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)

Yazar: McHardy, Tatiana, Caldwell, John J., Cheung, Kwai-Ming, Hunter, Lisa J., Taylor, Kevin, Rowlands, Martin, Ruddle, Ruth, Henley, Alan, de Haven Brandon, Alexis, Valenti, Melanie, Davies, Thomas G., Fazal, Lynsey, Seavers, Lisa, Raynaud, Florence I., Eccles, Suzanne A., Aherne, G. Wynne, Garrett, Michelle D., Collins, Ian
Baskı/Yayın Bilgisi 2010

Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate fo...

Yazar: Bavetsias, Vassilios, Crumpler, Simon, Sun, Chongbo, Avery, Sian, Atrash, Butrus, Faisal, Amir, Moore, Andrew S., Kosmopoulou, Magda, Brown, Nathan, Sheldrake, Peter W., Bush, Katherine, Henley, Alan, Box, Gary, Valenti, Melanie, de Haven Brandon, Alexis, Raynaud, Florence I., Workman, Paul, Eccles, Suzanne A., Bayliss, Richard, Linardopoulos, Spiros, Blagg, Julian
Baskı/Yayın Bilgisi 2012

Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors

Yazar: Lainchbury, Michael, Matthews, Thomas P., McHardy, Tatiana, Boxall, Kathy J., Walton, Michael I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., de Haven Brandon, Alexis K., Box, Gary, Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Garrett, Michelle D., Collins, Ian
Baskı/Yayın Bilgisi 2012

Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655: pharmacodynamic and predictive potential in metastatic melanoma

Yazar: Ang, Joo Ern, Pal, Akos, Asad, Yasmin J, Henley, Alan T, Valenti, Melanie, Box, Gary, de haven Brandon, Alexis, Revell, Victoria L, Skene, Debra.J, Venturi, Miro, Rueger, Ruediger, Meresse, Valerie, Eccles, Suzanne A, de Bono, Johann S, Kaye, Stanley B, Workman, Paul, Banerji, Udai, Raynaud, Florence.I
Yayımlandı Mol Cancer Ther (2017)

Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736

Yazar: Moore, Andrew S., Faisal, Amir, Mak, Grace W. Y., Miraki-Moud, Farideh, Bavetsias, Vassilios, Valenti, Melanie, Box, Gary, Hallsworth, Albert, de Haven Brandon, Alexis, Xavier, Cristina P. R., Stronge, Randal, Pearson, Andrew D. J., Blagg, Julian, Raynaud, Florence I., Chopra, Rajesh, Eccles, Suzanne A., Taussig, David C., Linardopoulos, Spiros
Yayımlandı Blood Adv (2020)

Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

Yazar: Yap, Timothy A., Walton, Mike I., Hunter, Lisa-Jane K., Valenti, Melanie, de Haven Brandon, Alexis, Eve, Paul D., Ruddle, Ruth, Heaton, Simon P., Henley, Alan, Pickard, Lisa, Vijayaraghavan, Gowri, Caldwell, John J., Thompson, Neil T., Aherne, Wynne, Raynaud, Florence I., Eccles, Suzanne A., Workman, Paul, Collins, Ian, Garrett, Michelle D.
Yayımlandı Mol Cancer Ther (2010)

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer

Yazar: Wagner, Steve, Vlachogiannis, Georgios, De Haven Brandon, Alexis, Valenti, Melanie, Box, Gary, Jenkins, Liam, Mancusi, Caterina, Self, Annette, Manodoro, Floriana, Assiotis, Ioannis, Robinson, Penny, Chauhan, Ritika, Rust, Alistair G., Matthews, Nik, Eason, Kate, Khan, Khurum, Starling, Naureen, Cunningham, David, Sadanandam, Anguraj, Isacke, Clare M., Kirkin, Vladimir, Valeri, Nicola, Whittaker, Steven R.
Yayımlandı Oncogene (2018)

Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer

Yazar: Wagner, Steve, Vlachogiannis, Georgios, De Haven Brandon, Alexis, Valenti, Melanie, Box, Gary, Jenkins, Liam, Mancusi, Caterina, Self, Annette, Manodoro, Floriana, Assiotis, Ioannis, Robinson, Penny, Chauhan, Ritika, Rust, Alistair G., Matthews, Nik, Eason, Kate, Khan, Khurum, Starling, Naureen, Cunningham, David, Sadanandam, Anguraj, Isacke, Clare M., Kirkin, Vladimir, Valeri, Nicola, Whittaker, Steven R.
Yayımlandı Oncogene (2019)

CCT244747 is a novel, potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs

Yazar: Walton, Mike I, Eve, Paul D, Hayes, Angela, Valenti, Melanie R, De Haven Brandon, Alexis K, Box, Gary, Hallsworth, Albert, Smith, Elizabeth L, Boxall, Kathy J, Lainchbury, Michael, Matthews, Thomas P, Jamin, Yann, Robinson, Simon P, Aherne, G Wynne, Reader, John C, Chesler, Louis, Raynaud, Florence I, Eccles, Suzanne A, Collins, Ian, Garrett, Michelle D
Baskı/Yayın Bilgisi 2012

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Yazar: Raynaud, Florence I., Eccles, Suzanne A., Patel, Sonal, Alix, Sonia, Box, Gary, Chuckowree, Irina, Folkes, Adrian, Gowan, Sharon, De Haven Brandon, Alexis, Di Stefano, Francesca, Hayes, Angela, Henley, Alan T., Lensun, Letitia, Pergl-Wilson, Giles, Robson, Anthony, Saghir, Nahid, Zhyvoloup, Alexander, McDonald, Edward, Sheldrake, Peter, Shuttleworth, Stephen, Valenti, Melanie, Wan, Nan Chi, Clarke, Paul A., Workman, Paul
Baskı/Yayın Bilgisi 2009